-
<![CDATA[Smoldering Multiple Myeloma: An Overview for Newly Diagnosed Patients]]>
31 Jan 2026 19:20 GMT
… : The Asymptomatic Bridge
Smoldering multiple myeloma is a precancerous condition characterized … patients with high-risk smoldering multiple myeloma, representing an opportunity to … damage and progression to multiple myeloma although preserving quality of …
-
<![CDATA[Optimizing Treatment Sequencing Before Third Line CAR T-Cell Therapy in Multiple Myeloma ]]>
30 Jan 2026 17:53 GMT
… patients with relapsed or refractory multiple myeloma who do not receive second …
-
<![CDATA[Prior BCMA and Bispecific Therapies and Their Impact on CAR T Sequencing in Multiple Myeloma ]]>
30 Jan 2026 17:54 GMT
… T cell therapy planning in multiple myeloma. Dr. Raje and colleagues emphasize …
-
FDA’s Multiple Myeloma Guidance Highlights Decade of Success
30 Jan 2026 16:52 GMT
… seeking accelerated approval of multiple myeloma therapies use the endpoint … codify MRD into approvals for multiple myeloma.
“Multiple myeloma is really the pioneer … support MRD-based approvals in multiple myeloma.
Randomized trials are recommended, …
-
Early management of multiple myeloma precursor cuts death risk by 47%: study
30 Jan 2026 06:56 GMT
… patients with asymptomatic or symptomatic multiple myeloma, the research team selected … progressed from asymptomatic to symptomatic multiple myeloma after prior MGUS detection … patients diagnosed directly with multiple myeloma without a documented precursor …
-
MiR-503-5p: A Biomarker for DVT in Multiple Myeloma
30 Jan 2026 02:31 GMT
… condition frequently encountered in multiple myeloma patients. The collaborative … the underlying mechanisms linking multiple myeloma and DVT remain inadequately … biomarker, deep venous thrombosis, multiple myeloma, cancer research, thrombosis, precision …
-
<![CDATA[FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma]]>
30 Jan 2026 02:21 GMT
… therapy for relapsed/refractory multiple myeloma. News release. Leads Biolabs. January … patients with relapsed/refractory multiple myeloma. Blood. 2025;146(suppl 1 … antibody, for the treatment of multiple myeloma. News release. Leads Biolabs. …
-
<![CDATA[FDA Fast Tracks LBL-034 in Relapsed or Refractory Multiple Myeloma]]>
29 Jan 2026 21:58 GMT
… patients with relapsed or refractory multiple myeloma.
The regulatory development was announced … patients with relapsed or refractory multiple myeloma sooner than might be … Therapy for Relapsed/Refractory Multiple Myeloma,” news release; https:/…
-
<![CDATA[Comparing Teclistamab Trial Designs for Early Relapsed Multiple Myeloma]]>
29 Jan 2026 19:26 GMT
Roberto Mina, MD, associate professor of hematology at the Winship Cancer Institute at Emory University, highlighted the pivotal role of B-cell maturation antigen (BCMA) targeting therapies. Mina noted that while several trials, including those involving …
-
<![CDATA[New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma]]>
29 Jan 2026 17:25 GMT
… multiple myeloma, transplant-ineligible multiple myeloma, and relapsed multiple myeloma.
Smoldering Myeloma
Regarding patients with smoldering multiple myeloma … -Ineligible Multiple Myeloma
In the management of transplant-ineligible multiple myeloma, the …